Toroidal soft x-ray array on the EXL-50 spherical tokamak.

A toroidal soft x-ray array system for spectrum and intensity measurements on the EXL-50 spherical tokamak is described. Silicon drift detectors and digital multichannel analyzers are adopted for all 21 channels of the array, and an average energy resolution of 147 eV at 5.89 keV has been achieved at count rates over 500 kcps. In total, 20 channels of the array are symmetrically observed in both co- and counter-current directions on the EXL-50 mid-plane with a spatial resolution of around 10 cm, and the remaining one serves as a background reference channel. Tungsten emissions from tungsten coating of the limiters on the central post are observed. The influence of hard x rays on measured soft x-ray spectra and system operation is discussed.

High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis.

Our study examined the relationship between the expression of matrix metalloproteinases (MMP)-1, MMP-2, and MMP-9 proteins and the pathogenesis of osteoarthritis (OA). We employed rigorous inclusion and exclusion criteria in computer-based bibliographic databases to extract published studies relevant to this investigation. The STATA 12.0 software was used for the statistical analyses. A total of 1408 studies were initially searched, and 10 studies with 458 OA patients and 295 healthy controls were included in this meta-analysis. The meta-analysis results suggested that the protein levels of MMP-1, MMP-2, and MMP-9 were higher in patients with OA than those in the control group. A subgroup analysis according to ethnicity showed that the protein levels of MMP-1 and MMP-2 were higher in Asian patients with OA than in controls. Caucasians showed no statistically significant differences in protein expression of MMP-1 and MMP-2 between the OA patient group and the control group. Interestingly, the protein levels of MMP-9 in patients with OA were higher than those in the control group in both Asians and Caucasians. A sample-source analysis suggested that the serum levels of MMP-2 and MMP-9 proteins were higher in patients with OA than in controls, while MMP-1 and MMP-9 protein expressions were higher in the synovial joint fluid of patients with OA than in controls. In conclusion, our meta-analysis results suggested that the increased expression of MMP-1, MMP-2, and MMP-9 proteins might be associated with the pathogenesis of OA.

Apoptosis induction and cell cycle perturbation in established cell lines by peroxysomicine A1 (T-514).

Peroxysomicine A1, a novel potential anticancer compound induced cell death in established cell lines and in a primary culture of rat neonatal cardiomyocytes. Non-transformed cells are less sensitive to the compound than transformed cell lines. Fluorescent microscopy of dying cells stained with DNA-specific dyes revealed chromatin condensation and nuclear fragmentation as well as membrane blebbing characteristic of apoptosis. Flow cytometry of cells treated with peroxysomicine A1, demonstrated appearance of cells containing less than 2C DNA, that indicated degradation of nuclear DNA, another hallmark of apoptotic cell death. Z-VAD, a nonspecific caspase inhibitor, prevented DNA fragmentation but not cell death registered by permeabilization of cell outer membrane. Peroxysomicine A1 also inhibited proliferation of various cell lines. Flow cytometry analysis showed significant accumulation of dividing cells in G2/M phases of cell cycle indicating, most likely delay in G2. These results provide initial insight into the mechanisms of action of peroxysomicine A1 and suggest that peroxysomicine A1 is a potent inhibitor of cell proliferation and inducer of apoptosis and may be a useful antineoplastic chemotherapeutic agent.

Analysis of ovariectomy and estrogen effects on body composition in rats by X-ray and magnetic resonance imaging techniques.

Resistance of bone to fracture--bone strength--has been shown to depend on both the amount of bone and its architectural spatial organization. In vivo magnetic resonance (MR) techniques have the capability of imaging bone tissue, including the trabecular microarchitecture and the marrow composition. We have applied in vivo and ex vivo MR methods to the tibia in an ovariectomized rat model of osteoporosis. Specifically, in vivo high-resolution three-dimensional MR imaging and localized MRS were facilitated by specialized coils and high field magnets, resulting in enhanced sensitivity of detection. As a result, in vivo and ex vivo differences in marrow composition were found between sham-ovariectomized, ovariectomized, and ovariectomized animals treated with 17-beta-estradiol. Estrogen effects were detected in vivo 7 days after surgery (3 days into treatment) as a decrease in the tibial fat signal level. The in vivo effects of ovariectomy were observed 56 days after surgery as an increase in MR image fat signal level and spectral fat/water ratio in the proximal tibia. Ex vivo measurements of tibial marrow water signal discriminated clearly between the sham and ovariectomized groups and showed increased individual variations in the treatment group. Imaging further showed that the highest fat content is observed in the epiphysis. Computed tomography confirmed ovariectomy-induced loss of bone in the proximal tibial metaphysis compared with the sham group. This loss of cancellous bone with ovariectomy is consistent with the MR observations of increases in both fat and water in the metaphysis. These data showed that MR techniques complement X-ray techniques in the bone, water, and fat compositional analysis of the appendicular skeleton in response to ovariectomy and pharmacological treatment.

Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus macaques.

Biomechanical and quantitative computed tomography (QCT) analyses showed beneficial effects of parathyroid hormone (PTH (1-34)) on lumbar vertebrae from ovariectomized monkeys, even after withdrawal of treatment for 6 months. Adult cynomolgus monkeys were randomized, ovariectomized (except for sham ovariectomy controls), and treated subcutaneously with vehicle (OVX) or 5 micrograms/kg per day PTH (1-34) (PTH5) for 18 months. An additional group was treated subcutaneously with 5 micrograms/kg per day PTH (1-34) (PTH5W) for 12 months and then switched to vehicle for the remaining 6 months. Lumbar vertebrae were excised at necropsy, and L5 were serially scanned by QCT, using 70 x 70 x 500 microns voxels. PTH increased volumetric bone mineral density (BMD, mg/cm3) and bone mineral content (BMC, mg) for both PTH5 and PTH5W compared with OVX and Sham without inducing hypermineralization, without stimulating periosteal expansion, and without significant constriction of the neural canal. BMD values for the voxels were then averaged to create nearly isotropic voxels of 490 x 490 x 500 microns. Serial scans were stacked and a triangular surface mesh generated for each bone, using a 'marching cubes' algorithm. A smoothed version of each surface mesh was used to generate a tetrahedral element for three-dimensional finite element modeling. An isotropic Young's modulus for each tetrahedral element was calculated as a function of the original voxel BMDs. Linear elastic stress analysis was then performed for each finite element model in which a distributed load of 100 newtons (N) was applied to the top surface of the centrum, perpendicular to the bottom surface with the bottom surface constrained in the direction of loading. Analysis of the effective strain showed considerable reduction in vertebral strain for both PTH5 and PTH5W, compared with OVX. Compression testing of the adjacent L3 and L4 confirmed that vertebral strength and stiffness for PTH5 and PTH5W were significantly greater than for OVX. Histogram and QCT analyses showed PTH conversion of low-density bone (trabecular bone) into medium-density bone (more and thicker trabeculae) by stimulating bone apposition. PTH withdrawal induced conversion of medium-density into low-density and high-density bone with the latter higher than in OVX. These data show that even transient PTH treatment improves vertebral architecture and bone quality to reduce the likelihood of fracture, and that transient treatment is better than no PTH treatment at all.

LY353381 x HCl: an improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34).

LY353381 x HCl is a benzothiophene analog that is structurally related to raloxifene with potent selective estrogen receptor modulator activity in the ovariectomized rat model of postmenopausal osteoporosis. The effects of LY353381 x HCl on bones, body weight, and uterine weight were evaluated in 7-month-old rats with osteopenia that was induced by ovariectomizing animals for 1 month before initiation of treatment with several agents individually, in combination, or in sequence. LY353381 x HCl was administered daily by itself for 90 days, in combination with the amino-terminal fragment of PTH-(1-34) (PTH) for 90 days, or sequentially after PTH when PTH was discontinued after 45 days of treatment. Additionally, comparisons were made of animals treated with PTH alone, 17alpha-ethynyl estradiol alone, equine estrogens (Premarin) alone, raloxifene alone, or combinations of PTH and equine estrogens or raloxifene. Ovariectomy induced increases in the rate of bone turnover and body weight while decreasing bone mineral density, bone mineral content, bone strength, trabecular bone volume, trabecular thickness, trabecular number, and uterine weight. LY353381 x HCl at 0.01-1 mg/kg had marginal effects on body weight and no effect on uterine weight compared with those in ovariectomized controls, in contrast to 17alpha-ethynyl estradiol or equine estrogens. LY353381 x HCl prevented further bone loss due to ovariectomy in tibia, femora, and lumbar vertebra, like 17alpha-ethynyl estradiol but unlike equine estrogens. LY353381 x HCl prevented the resorption of trabecular bone spicules, like 17alpha-ethynyl estradiol, but inhibited bone formation activity to a lesser extent than 17alpha-ethynyl estradiol. In this model, 17alpha-ethynyl estradiol appeared to be more efficacious after 3 months of treatment than equine estrogens in the proximal tibia metaphysis, suggesting efficacy differences between metabolites of 17beta-estradiol in bone. PTH at 10 microg/kg had no effect on body weight or uterine weight, but significantly increased bone mass to beyond those in sham-operated controls, baseline controls, and groups receiving other individual treatments at both axial and appendicular sites. The combination of LY353381 x HCl and PTH increased bone mass at a faster rate and to a greater extent than PTH alone or the combinations of equine estrogens/PTH and raloxifene/PTH at trabecular bone sites. The LY353381 x HCl/PTH combination improved bone mass and quality beyond any agent alone in regions enriched for cancellous bone, but was not significantly better than PTH alone on cortical bone. Additionally, when PTH was discontinued at 45 days, LY353381 x HCl prevented the rapid loss of bone observed in controls. Therefore, LY353381 x HCl appears to be useful by itself, in combination, or in sequence with PTH to replace lost bone in postmenopausal women.

Effects of monoclonal antibody directed to LeY on implantation in the mouse.

The role of carbohydrates in embryo implantation in the mouse was investigated using an embryo transfer model and a blastocyst-uterine epithelial cell co-culture system. The monoclonal antibody (mAb) AH6 directed to LeY oligosaccharide (Fuc alpha1-2 Gal beta 1-4 [Fuc alpha1-3] GlcNAc) and other three mAbs directed to carbohydrates whose structures are closely related to LeY were used to show the effect of carbohydrate specificity on implantation. In the embryo transfer model, donor blastocysts (4 days post-coitus) were pretreated with mAb AH6 (experimental) or other mAbs (control) and transferred into one uterine horn of a recipient. The implantation rate was checked after 5 days. Implantation was significantly inhibited by mAb AH6 pretreatment, and inhibition was not observed in control groups. In the co-culture system, the attachment and outgrowth rate of blastocysts on the surface of uterine epithelial cells was significantly inhibited when monolayer epithelial cells or blastocysts were pretreated with mAb AH6. The most obvious effect of mAb AH6 was obtained during 2-4 h co-incubation. No inhibition was observed in the control groups. It was, therefore, concluded that oligosaccharide LeY recognized by mAb AH6 plays an essential role at the initial stage of implantation. It may act as a mediator molecule for adhesion between the surface of blastocyst and epithelial cell, and its function is carbohydrate-specific.

Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats.

For the first time, PTH (1-34) was found to significantly affect bone quality, femora length, and body weight of aged, ovariectomized rats. Specifically, we examined the effects of biosynthetic human PTH (1-34) in 9 month-old rats that were ovariectomized and dosed for the ensuing 6 months with 8 or 40 microg/kg PTH. Bone content, architecture, and quality of axial and appendicular skeletal sites were analyzed by computed tomography (QCT), histomorphometry, and biomechanical testing. The large sample size (n = 26-35) of this study was useful in confirming the anabolic, dose-dependent effects of PTH at trabecular and cortical bone sites. Longitudinal analysis of tibias by QCT confirmed a small age-dependent reduction in bone density, with further reductions observed for ovariectomized controls (OVX). Subtle but deleterious effects of ovariectomy on bone quality are described. Additionally, the strength of the femoral neck was shown not to differ between baseline, sham-operated controls, or OVX in this model, suggesting limited utility of this measurement in aged rats. Both doses of PTH induced substantial gains above OVX, in bone mass and connectivity for the proximal tibia, distal femur, proximal femur, and spine. Ovariectomy significantly decreased the toughness of vertebral bone. However, PTH at 8 microg/kg reversed this deleterious effect on bone quality, while 40 microg/kg PTH significantly improved both toughness and brittleness beyond baseline controls. Cortical bone analyses at the femoral or tibial diaphysis confirmed the PTH stimulation of endosteal and periosteal bone formation with resulting increase in cortical thickness, moment of inertia, strength, and stiffness of the femur. PTH treatment significantly improved the intrinsic properties, Young's modulus and toughness, of the femur compared with OVX. At 40 microg/kg PTH, bone mass and strength were typically greater than sham or baseline controls, confirming that PTH is functionally anabolic at trabecular and cortical bone sites. Interestingly, PTH dose-dependently increased the femora length, in the absence of differences between baseline, sham, and OVX controls. PTH slightly increased body weight above OVX. In addition, PTH did not interfere with the beneficial effects of ovariectomy on rat longevity.

Adenovirus E1A inhibits cardiac myocyte-specific gene expression through its amino terminus.

Adenovirus E1A oncoproteins inhibit muscle-specific gene expression and myogenic differentiation by suppressing the transcriptional activating functions of basic helix-loop-helix proteins. As one approach to identifying cardiac-specific gene regulatory proteins, we analyzed the functional regions of E1A proteins that are required for muscle gene repression in cardiac cells. Myocyte-specific promoters, including the alpha-actins and alpha-myosin heavy chain, were selectively and potently inhibited (>90%) by E1A, while the ubiquitously expressed beta-actin promoter was only partially ( approximately 30%) repressed; endogenous gene expression was also affected. Distinct E1A protein binding sites mediated repression of muscle-specific and ubiquitous actin promoters. E1A-mediated inhibition of beta-actin required both an intact binding site for the tumor repressor proteins pRb and p107 and a second E1A domain (residues 15-35). In contrast, cardiac-specific promoter repression required the E1A amino-terminal residues 2-36. The proximal skeletal actin promoter (3' to base pair -153) was a target for repression by E1A. Although E1A binding to p300 was not required for inhibition of either promoter, co-expression of p300 partially reversed E1A-mediated transcriptional repression. We conclude that cardiac-specific and general promoter inhibition by E1A occurs by distinct mechanisms and that cardiac-specific gene expression is modulated by cellular factors interacting with the E1A p300/CBP-binding domain.

[Studies of murine ectoplacental cone cells interaction with laminin].

Implantation of the mouse embryo is dependent on the interactions between the trophoblast cells and the surrounding uterine environment. The initial invasion by primary trophoblast stimulates the uterine stromal fibroblasts differentiate into decidual cells, which deposit a pericellular matrix consisting of LN, FN and Col IV. The secondary trophoblast giant cells (TGCs) from ectoplacental cone (EPC) invade the decidua to form the fetal portion of the placenta. We used synthetic peptides cyclic YIGSR (cYIGSR) and RGDS to study the mechanisms of EPC cells interaction with LN. The results indicated that cYIGSR and RGDS promoted EPC attachment and had synergistic effect, and cYIGSR also promoted EPC outgrowth and secondary TGCs migration. LN supported EPC attachment and outgrowth, as well as secondary TGCs migration from EPC. Biologically active domains RGD of LN A chain and YIGSR of LN B1 chain participated synergistically in EPC attachment, outgrowth, as well as secondary TGCs migration. Since synthetic peptides cYIGSR and RGDS can't competitively inhibit EPC attachment with LN completely, there must be other binding sites involved in the interaction.

Platelet adhesion to cultured bovine cerebral microvascular endothelial cells by stimulation of platelet activating factor and antagonism of drugs.

AIM: To study platelet activating factor (PAF) stimulating the platelets to adhere to cultured bovine cerebral microvascular endothelial cells (CMEC) and the inhibitory effect of triazelodiazepine (WEB), 1,5-bis-(3,4-dimethoxyphenyl)-tetrahydro-(4H)-pyran (DMPP), tetrandrine (Tet). METHODS: The platelets adhesion to CMEC and the inhibitory effect of drugs were investigated by [3H]adenine labeling of rabbit blood platelet. RESULTS: The platelet adhesion to CMEC was increased by 36% vs control after CMEC was stimulated with PAF 10 nmol L-1 for 25 min. WEB 0.1, 1, 10 mmol L-1 or DMPP 0.1, 1, 10 mmol L-1 or Tet 0.1, 1, 10 mmol L-1 inhibited the PAF stimulating platelet adhesion to CMEC by 5.4%, 16.3%, 20.1%; 13.7%, 19.4%, 22.4%; and 5.5%, 23.1%, 32.6%, respectively. CONCLUSION: DMPP and Tet inhibited the PAF action in cerebral vascular system.

Cloning and mutagenesis of the rabbit ApoB mRNA editing protein. A zinc motif is essential for catalytic activity, and noncatalytic auxiliary factor(s) of the editing complex are widely distributed.

Apolipoprotein (apo) B mRNA editing is the specific deamination of cytidine (nucleotide 6666) to uridine in apoB mRNA. We isolated a full-length cDNA clone encoding the rabbit apoB mRNA editing protein (REPR), a subunit of the editing complex. Rabbit REPR is analogous to a rat enterocyte 27-kDa protein that has been shown to have cytidine deaminase activity. Like rat REPR, rabbit REPR edited synthetic apoB RNA when mixed with chicken enterocyte extract. Surprisingly, the REPR also acquired editing activity when mixed with extracts from various organs of the rabbit (liver, gallbladder, stomach, intestine, adrenals, thyroid, testes, spleen, kidney, and lung) or the chicken (kidney and liver). In contrast, the rabbit REPR mRNA was found only in the small and large intestine. Thus, the auxiliary protein(s) of the apoB mRNA editing complex, which are essential for editing activity, exist in organs devoid of significant apoB mRNA editing or apoB synthesis. REPR requires zinc for its catalytic activity. We mutated putative zinc-coordinating residues (His61, Cys93, Cys96) and 2 additional residues (Glu63, Pro92) of the rabbit REPR that are conserved in other cytidine or deoxycytidylate deaminases and in rat REPR. The wild-type and mutant REPR cDNAs each produced 28-kDa proteins when transcribed and translated in vitro. Compared with the wild-type editing activity, the mutations of His61-->Ala, Glu63-->Ala, Cys93-->Ala, and Cys96-->Ala abolished or greatly reduced editing activity, whereas the mutations of His61-->Cys (which also can coordinate zinc) and Pro92-->Ala had a lesser effect. These results indicate that His61, Cys93, and Cys96 are essential for editing activity, probably because they coordinate zinc, whereas Glu63 also is essential, because it may be involved in the deaminase reaction. In addition, the widespread distribution of the auxiliary factor(s) portends their involvement in other RNA editing reactions.

[Effects of calcimycin on platelet adhesion to cultured bovine cerebral microvascular endothelial cells and its antagonism by drugs].

Calcimycin induced rabbit platelet adhesion to cultured bovine cerebral microvascular endothelial cells (CMEC) and its inhibition by triazelodiazepine (WEB 2086), 1,5-bis-(3,4-dimethoxyphenyl)-tetrahydro-(4H)-pyran (DMPP) and tetrandrine (Tet) were investigated. The results showed that calcimycin significantly increased platelet adhesion to CMEC. The platelet adhesion to CMEC was increased by 17.1% vs control after stimulation with calcimycin 0.01 mumol.L-1 for 25 min. WEB 2086 0.1, 1.0 and 10.0 mumol.L-1 or DMPP 0.1, 1.0 and 10.0 mumol.L-1 or Tet 0.1, 1.0 and 10.0 mumol.L-1 inhibited the calcimycin induced platelet adhesion to CMEC by 9.0, 22.9 and 23.1% or 9.7, 15.6 and 22.1% or 7.8, 15.6 and 24.6%, respectively. This indicates that DMPP and Tet may have perspectives in the prevention and treatment of cerebral vascular diseases.

[Drug antagonism of TNF induced proliferation of bovine cerebromicrovascular smooth muscle cells].

Effects of tumor necrosis factor (TNF) on the proliferation of bovine cerebromicrovascular smooth muscle cells (BCSMC) were investigated. At concentrations from 50 to 5000 U.ml-1, TNF was shown to induce proliferation of cultured BCSMC in a dose-dependent manner. After 24 h incubation of the cells, TNF significantly stimulated the proliferation of BCSMC and reached maximal effects after 48 h incubation, then the effects slightly decreased. At concentrations from 10(-6) to 10(-4) mol.L-1, both imperatorin (Imp) and iso-imperatorin (Isi) were found to antagonize the TNF induced proliferation of BCSMC. Their maximal inhibitory effects were 42.2 and 36.1% at 10(-4) mol.L-1 respectively. 6-(alpha,alpha-diphenylacetylpiperazinly) phenyl-5-methyl-4,5-dihydro-3 (2H)-pyridazinone (DMDP) and 6-(alpha-phenylacetylpiperazinyl) phenyl-5-methyl-4,5-dihydro-3(2H)-pyridazinone (PMDP) were also found to possess similar effect at lower concentration (10(-6) mol.L-1), but no significant effect was observed when the drug concentration was higher.

Development of bovine embryos in vitro as affected by energy substrates.

Simple media were developed to study the metabolic requirements of bovine embryos up to Day 7 (Day 0 = day of oocyte aspiration) in vitro. Embryos were derived from oocytes matured and fertilized in vitro. At 45 +/- 2 h post insemination, embryos (> or = 2 cells) were randomly allotted to treatments. Examined in experiments 1 and 3 was the effect of pyruvate concentration in the presence of lactate. In the presence of lactate, pyruvate (0.2-5.0 mM) had no effect (p > 0.05) on the percentage of morulae or blastocysts. However, increasing the concentration of hemicalcium L-lactate from 5 mM to 10 mM decreased (p < 0.001) the percentage of embryos reaching the morula or blastocyst stage (experiment 3). Neither magnesium sulfate (0.5 mM) nor EDTA (10 mM) improved embryo development when added to the medium CR1 (experiment 2). Increasing the calcium level to 5 mM or the lactate level to 10 mM had no effect (p > 0.05) on embryo development (experiment 4). However, the interaction of adding calcium and lactate resulted in a decreased (p < 0.05) percentage of morulae. Determined in experiment 6 were the independent effects of pyruvate, lactate, and glucose on embryo development in vitro. As pyruvate or lactate level was increased from 1 to 10 mM, the percentage of blastocysts was decreased (p < 0.05). These experiments indicate that adding pyruvate to a medium containing lactate is not necessary for development of bovine embryos in vitro.

Dauricine and anisodamine inhibited leukotrienes- and platelet activating factor-induced DNA synthesis and proliferation of bovine cerebral microvascular smooth muscle cells in culture.

The effects of leukotrienes (LT) and platelet activating factor (PAF) on DNA synthesis and proliferation of bovine cerebral microvascular smooth muscle cells (BCMSMC) were studied. At 100 pmol.L-1, LTB4, LTC4, LTD4, and PAF promoted the DNA synthesis by 44%, 50%, 48%, and 57%, and enhanced the cell proliferation by 33%, 47%, 27%, and 40%, respectively. Dauricine and anisodamine inhibited the DNA synthesis of the cells induced by LT and PAF (0.1-100 mumol.L-1). These results indicate the bright future of the 2 drugs in the prevention and treatment of cerebral vascular diseases.

Effects of dauricine and tetrandrine on [3H] WEB 2086 specific binding to bovine anterior cerebral arterial smooth muscle cells in vitro.

By using [3H] WEB 2086, a PAF antagonist, specific binding sites of PAF on bovine anterior cerebral arterial smooth muscle cells was identified. Two populations of binding sites with different dissociation constants on the cells were found. The Kd-1 = 22.8 +/- 5.0 nmol.L-1, Kd-2 = 186 +/- 20.5 nmol.L-1 at 25 C. The total number of binding sites were Bmax-1 = 2.1 +/- 0.3 pmol/10(6) cells and Bmax-2 = 12.1 +/- 1.5 pmol/10(6) cells. Dauricine and tetrandrine, two active compounds with similar chemical structure extracted from traditional Chinese herbs, were found to inhibit [3H] WEB 2086 specific binding significantly in culture cells.

[Effects of 6-(alpha alpha-diphenylacetylpiperazinyl) phenyl-5-methyl-4,5-dihydro-3 (2H)-pyridazinone on rabbit platelet aggregation and TXB2, cAMP production].

6-(alpha alpha-diphenylacetylpiperazinyl) phenyl-5-methyl-4,5-dihydro-3 (2H)-pyridazinone (DMDP) is a new synthetic pyridazinone derivative. This compound was shown to inhibit AA, ADP and PAF-induced rabbit platelet aggregation, and its IC50s were found to be 1.12 +/- 0.1, 4.19 +/- 0.5 and 2.97 +/- 0.1 mumol/L, respectively. At the concentration range of 1-500 mumol/L, the compound was found to depress TXB2 content and to increase cAMP levels in washed rabbit platelets in a dose-dependent manner. These might be the mechanisms of the compound on the inhibition of rabbit platelets.